Kastner J, Hossain R. White CS. Epidemiology of Lung Cancer SEMIN ROENTGENOL. 2019;1(55):36–53.
Google Scholar
Yang D, Liu Y, Bai C, Wang X, Powell CA. Epidemiology of lung cancer and lung cancer screening programs in China and the United States. Cancer lett. 2020;468(5):82–7.
Article
CAS
PubMed
Google Scholar
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. Ca Cancer J Clin. 2017;67(1):7–30.
Article
PubMed
Google Scholar
Anish T, Yuanbin C, Tinghui Y, Marko J, Giuseppe G. Trends and Characteristics of Young Non-Small Cell Lung Cancer Patients in the United States. Front Oncol. 2015;5(33):113–9.
Google Scholar
Wilkes GM. Targeted Therapy Attacking Cancer with Molecular and Immunological Targeted Agents. Asia Pac J Oncol Nurs. 2018;5(2):137–55.
Article
PubMed Central
PubMed
Google Scholar
Singal G, Miller PG, Agarwala V, Li G, Kaushik G, Backenroth D, et al. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database. JAMA. 2019;321(14):1391–402.
Article
CAS
PubMed Central
PubMed
Google Scholar
Ettinger DS, Wood DE, Akerley W, Dhila. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. J Natl Compr Canc Netw. 2016;14(3):255–64.
Article
PubMed
Google Scholar
Wang MC, Wang CL, Chen TL, Chang WC, Lu JJ, Chang PY, et al. Predicting outcomes of EGFR-targeted therapy in non-small cell lung cancer patients using pleural effusions samples and peptide nucleic acid probe assay. Clin Chem Lab Med. 2017;55(12):1979–86.
Article
CAS
PubMed
Google Scholar
Kale HP, Mays D’AP, Nadpara PA, Slattum PW. Economic Burden Of Renal Cell Carcinoma Among Older Adults In The Targeted Therapy ERA. Urol Oncol. 2019;37:e19-28.
Article
Google Scholar
Varvaresou A, Iakovou K, Mellou F, Myrogiannis D, Papageorgiou S. Targeted therapy in oncology patients and skin: Pharmaceutical and dermocosmetic management. J Cosmet Dermatol-US. 2020;20(3):1–7.
Google Scholar
Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, et al. Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. J Clin Oncol. 2015;33(32):3817–25.
Article
CAS
PubMed Central
PubMed
Google Scholar
Tischer B, Huber R, Kraemer M, Lacouture ME. Dermatologic events from EGFR inhibitors: the issue of the missing patient voice. Support Care Cancer. 2017;25(2):651–60.
Article
PubMed
Google Scholar
Lee JL, Jeong Y. Quality of Life in Patients With Non-Small Cell Lung Cancer: Structural Equation Modeling. Cancer Nurs. 2018;42(6):475–83.
Barrios DM, Phillips GS, Freites-Martinez A, Hsu M, Lacouture ME. Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study. J Eur Acad Dermatol. 2019;34(6):27–39.
Google Scholar
Yagasaki K, Komatsu H, Soejima K, Naoki K, Hamamoto Y. Targeted Therapy-induced Facial Skin Toxicities: Impact on Quality of Life in Cancer Patients. Asia Pac J Oncol Nurs. 2018;5(2):172–7.
Article
PubMed Central
PubMed
Google Scholar
Chan JC, Lee YH, Liu CY, Shih HH, Tang WR. A Correlational Study of Skin Toxicity and Quality of Life in Patients With Advanced Lung Cancer Receiving Targeted Therapy. J NURS RES. 2019;27(6):51–9.
Article
Google Scholar
Sano K, Nakadate K, Hanada K. Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer. BMC Cancer. 2020;20(1):279–87.
Article
CAS
PubMed Central
PubMed
Google Scholar
Pouliot A, Vaillancourt R, Stacey D, Suter P. Defining and identifying concepts of medication literacy An international. Res Soc Admin Pharm. 2017;15(6):632–40.
Google Scholar
Cordina M, Meen-Anttila K, Lauri J, Tabone S, Enlund H. Health and medication literacy and the desire to participate in pharmacotherapy decision making – comparison of two countries. Res Social Adm Pharm. 2018;14(9):817–23.
Article
CAS
PubMed
Google Scholar
Chun-Hsien L, Chang FC, Sheng-Der H, Chi HY, Huang LJ, Ming-Kung Y, et al. Inappropriate self-medication among adolescents and its association with lower medication literacy and substance use. PLoS ONE. 2017;12(12): e189199.
Google Scholar
Miao NF, Wang TC, Chang FC, Lee CH, Chi HY, Huang LJ, et al. Prevalence and association of pain experiences, medication literacy, and use of medication among children and adolescents in Taiwan. J Pediatr Nurs. 2019;33(8):376–83.
Google Scholar
Persell SD, Karmali KN, Lazar D, Friesema EM. Effect of Electronic Health Record-Based Medication Support and Nurse-Led Medication Therapy Management on Hypertension and Medication Self-management A Randomized Clinical Trial. JAMA Intern Med. 2018;26(9):11–9.
Google Scholar
Yu SP, Mehta G, Kuo MG, et al. The Effect of Health Literacy on Medication Knowledge and Medication Discrepancy in Chinese Americans. J Pharm Technol. 2015;31(6):356–65.
Google Scholar
Tseng LC, Chen KH, Wang CL, Weng LC. Effects of tyrosine kinase inhibitor therapy on skin toxicity and skin-related quality of life in patients with lung cancer: An observational study. Med. 2020;99(23):205–10.
Google Scholar
Sauceda JA, Loya AM, Sias JJ, Taylor T, Wiebe JS, Rivera JO. Medication literacy in Spanish and English: psychometric evaluation of a new assessment tool. J Americ Pharma Associa. 2012;52(6):e231–40.
Article
Google Scholar
Zheng F, Zhong ZQ, Ding SQ, Luo AJ. Modification and evaluation of assessment of medication literacy. J Cent South Univ. 2016;41(11):1226–31.
Google Scholar
Barton-Burke M, Ciccolini K, Mekas M, Burke S. Dermatologic Reactions to Targeted Therapy: A Focus on Epidermal Growth Factor Receptor Inhibitors and Nursing Care. Nurs Clin N Am. 2017;1(52):83–113.
Article
Google Scholar
Yamamoto K, Yano I. Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma. Med Oncol. 2018;35(2):16–26.
Article
CAS
PubMed
Google Scholar
Deutsch A, Leboeuf NR, Lacouture ME, Mclellan BN. Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy. Proc Am Soc Clin Oncol. 2020;40(40):485–500.
Google Scholar
Chen CB, Wu MY, Yee NC, Lu CW, Wu J, Pei-Han K, et al. Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. Cancer Manag Res. 2018;10:1259–73.
Article
CAS
PubMed Central
PubMed
Google Scholar
Paul T, Schumann C, Rüdiger S, Boeck S, Heinemann V, Kachele V, et al. Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients. Eur J Cancer. 2014;50(11):1855–63.
Article
CAS
PubMed
Google Scholar
Cazzaniga ME, Danesi R, Girmenia C, Invernizzi P, Elvevi A, Uguccioni M. Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success. Breast Cancer Res Treat. 2019;176(3):483–94 ([Journal Article; Review]).
Article
PubMed Central
PubMed
Google Scholar
CLELL HASENBANK. Supportive Care and Management of Treatment-Emergent Adverse Events With Targeted Therapy in Non-Small Cell Lung Cancer. Journal of the Advanced Practitioner in Oncology. 2017;35(5):1277–85.
Google Scholar
Occhipinti M, Brambilla M, Galli G, Manglaviti S, Prelaj A, Ferrara R, et al. Drug-drug interactions (DDIs) in non-small cell lung cancer during chemotherapy-immunotherapy treatment. J Thorac Oncol. 2021;16(4):1257–65.
Article
Google Scholar
Kafatos G, Dube S, Burdon P, Demonty G, Flinois A, Leclerc M, et al. Management of EGFR Inhibitor-induced Skin Toxicity and Factors Impacting Patients’ Adherence to Skin Toxicity Treatment: Health Care Provider and Patient Surveys in European Oncology Centers - ScienceDirect. Clin Colorectal Canc. 2020;19(2):100–8.
Article
Google Scholar
Chan J, Lee Y, Liu C, Shih H. A Correlational Study of Skin Toxicity and Quality of Life in Patients With Advanced Lung Cancer Receiving Targeted Therapy. J Nurs Res. 2019;27(6):51–9.
Article
Google Scholar
Sano K, Nakadate K, Hanada K. Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer. BMC Cancer. 2020;20(1):279–87.
Article
CAS
PubMed Central
PubMed
Google Scholar
Braden RL, Anadkat MJ. EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infections. Support Care Cancer. 2016;24(9):3943–50.
Article
PubMed
Google Scholar
FISCHER-CARTLIDGE EA. Assessment and Management of Gastrointestinal Toxicities and Lab Abnormalities Related to Targeted Therapy. Seminars Oncol Nurs. 2014;30(3):183–9.
Article
Google Scholar
Orrevall Y, Tishelman C, Permert J, Cederholm T. Nutritional support and risk status among cancer patients in palliative home care services. SUPPORT CARE CANCER. 2009;17(2):153–61.
Article
CAS
PubMed
Google Scholar
Zhong Z, Ma G, Zheng F, Duan Y, Luo A. Medication Literacy in a Cohort of Chinese Patients Discharged With Essential Hypertension. Front Public Health. 2020;7(9):385.
Article
PubMed Central
PubMed
Google Scholar
Silva D, Gomes A, Lobo JM, Almeida V, Almeida IF. Management of skin adverse reactions in oncology. J Oncol Pharm Pract. 2020;26(7):1703–14.
Article
PubMed
Google Scholar
Sefah IA, Kordorwu HE, Essah DO, Kurdi A, Godman B. Prevalence and Determinants of Serious Spontaneously Reported Adverse Drug Events Among Three Outpatient Care Settings in Ghana: Findings and Implications. Value in Health Regional Issues. 2020;22(6):38–47.
Article
Google Scholar
Zhong Z, Zheng F, Guo Y, Luo A. Medication Literacy in a Cohort of Chinese Patients Discharged with Acute Coronary Syndrome. Inter J Envir Res. 2016;13(7):720–6.
Google Scholar
Zheng F, Ding S, Luo A, Zhong Z, Duan Y, Shen Z. Medication literacy status of outpatients in ambulatory care settings in Changsha. China J Inter Med Res. 2017;45(1):303–9.
Google Scholar
Kamal AK, Khalid W, Zulfiqar M, Muqeet A, Zaidi F, Gowani A, et al. The potential of m-Health-based interventions to improve medication literacy and adherence in non-communicable diseases in Pakistan. Int J Stroke. 2019;66(5):1235–43.
Google Scholar
Cordinaa M, Hämeen-Anttilac K, Laurib J, Tabone S. Health and medication literacy and the desire to participate in pharmacotherapy decision making – comparison of two countries. Res Soc Admin Pharm. 2018;14(9):817–23.
Article
Google Scholar
Krajnovi, Du Anka, Ubavi, Stana, Bogavac-Stanojevi, A N. Pharmacotherapy Literacy and Parental Practice in Use of Over-the-Counter Pediatric Medicines. Medicina. 2019;51(22):985–92.
Staats H, Cassidy C, Kelso J, Mack S, Nemunaitis J. Targeted Molecular Therapy in Palliative Cancer Management. Biomed. 2020;5(13):27–49.
Google Scholar
Wu Y-L, Zhou C, Liam C-K, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label ENSURE study. Ann Oncol. 2015;26(9):1883–9.
Article
PubMed
Google Scholar
Sequist LV, James Chih-Hsin Y, Nobuyuki Y, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327–34.
Article
CAS
PubMed
Google Scholar
Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–8.
Article
CAS
PubMed
Google Scholar
Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46.
Article
CAS
PubMed
Google Scholar
Shi YK, Wang L, Han BH, et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomizedstudy. Ann Oncol. 2017;28(10):2443–50.
Article
CAS
PubMed
Google Scholar
Macdonald JB, Macdonald B, Golitz LE, Lorussoand P, Sekulic A. Cutaneous adverse effects of targeted therapies Part II: Inhibitors of the cellular membrane. J Am Acad Dermatol. 2015;72(2):221–38.
Article
CAS
PubMed
Google Scholar
Macdonald JB, Macdonald B, Golitz LE, et al. Cutaneous adverse effects of targeted therapies Part I: Inhibitors of the cellular membrane. J Am Acad Dermatol. 2015;72(2):203–20.
Article
CAS
PubMed
Google Scholar
Kim YS, Ji JH, Oh SY, Leeand S, Kang JH. A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor induced Skin Toxicities. Oncologist. 2019;25(1):2019–31.
Google Scholar
Honda Y, Hattori Y, Katsura S, et al. Stevens-Johnson syndrome-like erosive dermatitis possibly related to afatinib. Eur J Dermatol. 2016;26(4):413–4.
Article
PubMed
Google Scholar
Chen CB, Wu MY, Yee NC, et al. Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. Cancer Management & Research. 2018;10:1259–73.
Article
CAS
Google Scholar